Steven Bellon
Technik-/Wissenschafts-/F&E-Leiter bei FOGHORN THERAPEUTICS INC.
Vermögen: 1 Mio $ am 31.05.2024
Aktive Positionen von Steven Bellon
| Unternehmen | Position | Beginn | Ende |
|---|---|---|---|
| FOGHORN THERAPEUTICS INC. | Technik-/Wissenschafts-/F&E-Leiter | 10.01.2022 | - |
| Corporate Officer/Principal | 01.06.2016 | 10.01.2022 |
Karriereverlauf von Steven Bellon
Ehemalige bekannte Positionen von Steven Bellon
| Unternehmen | Position | Beginn | Ende |
|---|---|---|---|
| CONSTELLATION PHARMACEUTICALS, INC. | Direktor/Vorstandsmitglied | 01.09.2008 | 01.05.2016 |
| Corporate Officer/Principal | 01.09.2008 | 01.05.2016 |
Ausbildung von Steven Bellon
| Haverford College | Undergraduate Degree |
| Massachusetts Institute of Technology | Doctorate Degree |
Statistik
International
| Vereinigte Staaten | 5 |
Operativ
| Corporate Officer/Principal | 2 |
| Chief Tech/Sci/R&D Officer | 1 |
| Director/Board Member | 1 |
Sektoral
| Health Technology | 3 |
| Consumer Services | 2 |
| Finance | 2 |
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Unternehmensverbindungen
| Börsennotierte Unternehmen | 1 |
|---|---|
| FOGHORN THERAPEUTICS INC. | Health Technology |
| Private Unternehmen | 1 |
|---|---|
Constellation Pharmaceuticals, Inc.
 Constellation Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Constellation Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of novel therapeutics in the field of epigenetics. The firm utilizes epigenetics platform, which enables to validate targets and generate small molecules against these targets that selectively modulate gene expression in tumor and immune cells to drive anti-tumor activity. Its product include CPI-0610, CPI-1205, and CPI-0209. The company was founded by Danny Reinberg, David Allis, and Yang Shi on January 11, 2008 and is headquartered in Cambridge, MA. | Health Technology |
- Börse
- Insiders
- Steven Bellon
- Erfahrung
